Phase III Results Buoy Watson’s Benign Prostatic Hyperplasia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Silodosin would take on GSK’s Avodart and Pfizer’s Cardura XL.
You may also be interested in...
Rapaflo Approved For BPH; Watson Will Stress Unique Selectivity
Even sponsors not aiming for the benign prostatic hyperplasia market should take notice of the Oct. 8 approval of Watson Pharmaceuticals' Rapaflo (silodosin)
Rapaflo Approved For BPH; Watson Will Stress Unique Selectivity
Even sponsors not aiming for the benign prostatic hyperplasia market should take notice of the Oct. 8 approval of Watson Pharmaceuticals' Rapaflo (silodosin)
Watson-Kissei’s Silodosin For BPH Could Have Oct. 14 User Fee Date
FDA accepts Watson-Kissei’s NDA for silodosin to treat benign prostatic hyperplasia.